RCUS Fundamental Analysis - ARCUS BIOSCIENCES INC

Name: ARCUS BIOSCIENCES INC (RCUS) Stock
Brand: ARCUS BIOSCIENCES INC
Rating: 6.5 (3 reviews)

Fundamental Rating

Overall RCUS gets a fundamental rating of 2 out of 10. We evaluated RCUS against 533 industry peers in the Biotechnology industry. RCUS may be in some trouble as it scores bad on both profitability and health. RCUS is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year RCUS has reported negative net income.

RCUS had a negative operating cash flow in the past year.

RCUS had negative earnings in 4 of the past 5 years.

The reported operating cash flow has been mixed in the past 5 years: RCUS reported negative operating cash flow in multiple years.

1.2 Ratios

RCUS has a Return On Assets of -35.01%. This is in the better half of the industry: RCUS outperforms 63.23% of its industry peers.

RCUS has a Return On Equity (-78.21%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-35.01%
ROE	-78.21%
ROIC	N/A

ROA(3y)-24.17%

ROA(5y)-17.02%

ROE(3y)-55.15%

ROE(5y)-36.73%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RCUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RCUS does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, RCUS has more shares outstanding

The number of shares outstanding for RCUS has been increased compared to 5 years ago.

The debt/assets ratio for RCUS is higher compared to a year ago.

2.2 Solvency

RCUS has an Altman-Z score of 0.64. This is a bad value and indicates that RCUS is not financially healthy and even has some risk of bankruptcy.

RCUS has a better Altman-Z score (0.64) than 63.60% of its industry peers.

RCUS has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.

RCUS's Debt to Equity ratio of 0.22 is on the low side compared to the rest of the industry. RCUS is outperformed by 66.60% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.22
Debt/FCF	N/A
Altman-Z	0.64

ROIC/WACCN/A

WACC8.63%

2.3 Liquidity

A Current Ratio of 3.65 indicates that RCUS has no problem at all paying its short term obligations.

RCUS's Current ratio of 3.65 is in line compared to the rest of the industry. RCUS outperforms 45.03% of its industry peers.

A Quick Ratio of 3.65 indicates that RCUS has no problem at all paying its short term obligations.

RCUS has a Quick ratio (3.65) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.65
Quick Ratio	3.65

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

RCUS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.21%.

RCUS shows a decrease in Revenue. In the last year, the revenue decreased by -8.75%.

Measured over the past years, RCUS shows a very strong growth in Revenue. The Revenue has been growing by 76.65% on average per year.

EPS 1Y (TTM)-9.21%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-27%

Revenue 1Y (TTM)-8.75%

Revenue growth 3Y-12.33%

Revenue growth 5Y76.65%

Sales Q2Q%-45.83%

3.2 Future

The Earnings Per Share is expected to grow by 10.29% on average over the next years. This is quite good.

Based on estimates for the next years, RCUS will show a very strong growth in Revenue. The Revenue will grow by 25.22% on average per year.

EPS Next Y-20.18%

EPS Next 2Y-17.19%

EPS Next 3Y-6.71%

EPS Next 5Y10.29%

Revenue Next Year-9.21%

Revenue Next 2Y-25.56%

Revenue Next 3Y-8.39%

Revenue Next 5Y25.22%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RCUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCUS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as RCUS's earnings are expected to decrease with -6.71% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-17.19%

EPS Next 3Y-6.71%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RCUS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ARCUS BIOSCIENCES INC

NYSE:RCUS (11/25/2025, 8:09:39 PM)

After market: 23.8783 -0.4 (-1.65%)

24.28

+1.1 (+4.75%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-28 2025-10-28/amc

Earnings (Next)02-23 2026-02-23/amc

Inst Owners66.06%

Inst Owner Change-0.39%

Ins Owners5.33%

Ins Owner Change0.22%

Market Cap2.58B

Revenue(TTM)240.00M

Net Income(TTM)-341.00M

Analysts82.11

Price Target33.01 (35.96%)

Short Float %12.04%

Short Ratio6.01

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)52.48%

Min EPS beat(2)4.95%

Max EPS beat(2)100%

EPS beat(4)3

Avg EPS beat(4)28.92%

Min EPS beat(4)-8.41%

Max EPS beat(4)100%

EPS beat(8)6

Avg EPS beat(8)27.98%

EPS beat(12)10

Avg EPS beat(12)22.67%

EPS beat(16)13

Avg EPS beat(16)54.37%

Revenue beat(2)2

Avg Revenue beat(2)208.19%

Min Revenue beat(2)19.11%

Max Revenue beat(2)397.27%

Revenue beat(4)2

Avg Revenue beat(4)94.93%

Min Revenue beat(4)-24.87%

Max Revenue beat(4)397.27%

Revenue beat(8)6

Avg Revenue beat(8)97.65%

Revenue beat(12)8

Avg Revenue beat(12)69.17%

Revenue beat(16)11

Avg Revenue beat(16)103.35%

PT rev (1m)10.9%

PT rev (3m)10.9%

EPS NQ rev (1m)2.06%

EPS NQ rev (3m)-0.3%

EPS NY rev (1m)2.62%

EPS NY rev (3m)3.09%

Revenue NQ rev (1m)7.8%

Revenue NQ rev (3m)13.44%

Revenue NY rev (1m)2.06%

Revenue NY rev (3m)2.26%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	10.77
P/FCF	N/A
P/OCF	N/A
P/B	5.93
P/tB	5.93
EV/EBITDA	N/A

EPS(TTM)-3.44

EYN/A

EPS(NY)-4.26

Fwd EYN/A

FCF(TTM)-4.36

FCFYN/A

OCF(TTM)-4.34

OCFYN/A

SpS2.26

BVpS4.1

TBVpS4.1

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-35.01%
ROE	-78.21%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-24.17%

ROA(5y)-17.02%

ROE(3y)-55.15%

ROE(5y)-36.73%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score1

Asset Turnover0.25

Health

		Industry Rank	Sector Rank
Debt/Equity	0.22
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	20%
Cap/Sales	0.83%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.65
Quick Ratio	3.65
Altman-Z	0.64

F-Score1

WACC8.63%

ROIC/WACCN/A

Cap/Depr(3y)153.33%

Cap/Depr(5y)249.37%

Cap/Sales(3y)9.4%

Cap/Sales(5y)7.8%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-9.21%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-27%

EPS Next Y-20.18%

EPS Next 2Y-17.19%

EPS Next 3Y-6.71%

EPS Next 5Y10.29%

Revenue 1Y (TTM)-8.75%

Revenue growth 3Y-12.33%

Revenue growth 5Y76.65%

Sales Q2Q%-45.83%

Revenue Next Year-9.21%

Revenue Next 2Y-25.56%

Revenue Next 3Y-8.39%

Revenue Next 5Y25.22%

EBIT growth 1Y-25.84%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-10.25%

EBIT Next 3Y-2.73%

EBIT Next 5YN/A

FCF growth 1Y-51.58%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-60.58%

OCF growth 3YN/A

OCF growth 5YN/A

ARCUS BIOSCIENCES INC / RCUS FAQ

What is the ChartMill fundamental rating of ARCUS BIOSCIENCES INC (RCUS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RCUS.

What is the valuation status of ARCUS BIOSCIENCES INC (RCUS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ARCUS BIOSCIENCES INC (RCUS). This can be considered as Overvalued.

What is the profitability of RCUS stock?

ARCUS BIOSCIENCES INC (RCUS) has a profitability rating of 1 / 10.

What is the expected EPS growth for ARCUS BIOSCIENCES INC (RCUS) stock?

The Earnings per Share (EPS) of ARCUS BIOSCIENCES INC (RCUS) is expected to decline by -20.18% in the next year.

ARCUS BIOSCIENCES INC (RCUS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ARCUS BIOSCIENCES INC / RCUS FAQ

What is the ChartMill fundamental rating of ARCUS BIOSCIENCES INC (RCUS) stock?

What is the valuation status of ARCUS BIOSCIENCES INC (RCUS) stock?

What is the profitability of RCUS stock?

What is the expected EPS growth for ARCUS BIOSCIENCES INC (RCUS) stock?